Stock · CIPLA · Pharmaceuticals
CIPLA share price target 2026
Support, resistance, the F&O structure and the BazaarBaazi Crack Score for Cipla Limited, refreshed every end-of-day run. A systematic, data-only read on Cipla Limited: where it trades versus its 50-day and 200-day lines, the live 52-week range, and momentum. Refreshed from real price structure each run.
The verdict
BazaarBaazi reads CIPLA as two-way with a Crack Score of 76/100 as of 9 Jun 2026.
BazaarBaaziSource & method
Price target: support and resistanceComputed 9 Jun 2026
Support and resistance for CIPLA are read inside the latest show; no spot was printed in the most recent editorial note.
Levels are read inside the latest show. The most recent editorial reference is Systematic Read on 9 Jun 2026.
These are structural reference lines, not a SEBI-registered price target. BazaarBaazi is independent media; the levels frame how the desk reads the CIPLA chart, refreshed every end-of-day run.
The Crack Score, and how it is built76 / 100 · High conviction
The Crack Score is a deterministic 0 to 100 conviction number. Here is exactly what moved it for CIPLA, so the figure is a transparent signal rather than a vibe.
Base 50, adjusted by the factors above and clamped to 0 to 100. How the Crack Score works.
About Cipla LimitedBusiness profile
What CIPLA actually does, and the edge that holds its position.
Cipla's edge is breathing, literally, its decades in respiratory and inhalers is the hard-to-copy moat that separates it from plain-vanilla generics. It is one of India's largest drugmakers, strong in domestic branded generics and a US business built around complex and specialty molecules, with asthma and COPD inhaler formulations as a core competency. It also runs a growing South Africa and sub-Saharan Africa branded business and a North America biosimilars pipeline, but the inhaler franchise is where its differentiation truly sits.
Cipla's edge is its deep respiratory drug expertise and inhaler manufacturing capability, where complex device-drug combination products are harder for generics competitors to replicate than simple oral solid dosage forms. Its India brand strength in chronic therapy categories like respiratory, cardiology and HIV creates stickier revenue than the typical generics business.
The F&O viewHorizon · swing
How the futures and options structure on CIPLA reads right now.
The futures and options read on CIPLA leans to a two-way / range write. Strike-level positioning is read inside the latest show, against the printed spot. Single-stock F&O on CIPLA is thinner than the index, so open-interest shifts read with more noise; the desk weights price structure over raw OI. This is a structural reading of positioning, not a derivatives trade recommendation.
Why it movedLatest editorial line
The most recent BazaarBaazi read on what is driving CIPLA.
Systematic read: a disclosed, data-only model on real 1-year price structure.
Read in Systematic Read on 9 Jun 2026. Why CIPLA moved, the living explainer, tracks every move on one URL.
The 2026 to 2030 pictureStructural read
What genuinely drives CIPLA over a multi-year horizon. A structural read, not a price forecast.
From 2026 to 2030, the key drivers for Cipla are the US complex-inhaler pipeline (including gAdvair and other branded references) gaining approvals, the biosimilars opportunity through its North America pipeline, and sustained India branded-generic growth in chronic therapy. The key risk is a USFDA inspection action at any key facility or further delays in complex-inhaler approvals from the US regulator. What BazaarBaazi thinks: the respiratory expertise is a real, durable edge and the chronic-therapy India book is sticky, but the timing risk no score can pin down is the US regulator, the complex-inhaler approvals that the bull case rests on can slip quarter after quarter for reasons entirely outside Cipla's control.
What to watch:
- US complex inhaler approvals and launch ramp, especially gAdvair
- USFDA facility inspection outcomes across manufacturing sites
- India branded-generic revenue growth and chronic therapy market-share
- South Africa business performance as a geography-diversification gauge
- Biosimilar pipeline progress and any licensing or partnership deal flow
Peers and how to compare5 listed names
The listed names CIPLA is most often read against. Compare them on the same Crack Score and levels.
Sun Pharmaceutical Industries · SUNPHARMA
Read the SUNPHARMA verdict and levels
Dr Reddys Laboratories · DRREDDY
Read the DRREDDY verdict and levels
Divis Laboratories · DIVISLAB
Read the DIVISLAB verdict and levels
Lupin
Listed peer in the same space
Aurobindo Pharma
Listed peer in the same space
Live valuation readQ4 FY26 earnings · live spot
P/E, P/B, yield and the quality set for Cipla Limited, computed from the latest filed results times the live spot. The price-driven ratios (marked) refresh every session; ROE and margins hold until the next results.
P / E ·
28.9x
Earnings yield ·
3.46%
P / B ·
3.26x
P / S ·
4.03x
EV / EBITDA ·
17.7x
Dividend yield ·
0.94%
Market cap ·
Rs 1.12 lakh cr
Enterprise value ·
Rs 1.03 lakh cr
Stored from Cipla Limited's filed results, as of 2026-06-09 and currency-checked. Open the calculator, move the price and watch every ratio react.
Latest filed resultsQ4 FY26
Cipla Limited's most recent quarter, parsed straight from the official NSE filing. Every figure links back to its primary source.
Result Pulse
24 / 100Revenue
Rs 6,541 crNet profit
Rs 543 crEPS (quarter)
Rs 6.87| Growth | YoY | QoQ |
|---|---|---|
| Revenue | -2.8% | -7.5% |
| Net profit | -55.3% | -19.5% |
| Net margin | +8.3% | |
Figures are the Q4 FY26 result for CIPLA LIMITED, parsed straight from the official NSE integrated filing and verified to the paisa. The EPS shown is for the quarter, not a trailing-twelve-month figure, so it is not a P/E input.
What changed44 disclosures
Every recent official filing from Cipla Limited, straight from the exchange feed, with the BazaarBaazi Event Heat on the disclosure flow.
CIPLA LIMITED has filed 44 official disclosures recently. The most recent is a Dividend dated 08 Jun 2026.
Event Heat
59 / 100communication on tax deduction at source on final dividend for FY 2025-26
newspaper advertisement titled 'Notice of the 90th Annual General Meeting and E-voting Information
Event Heat is a dated net read of CIPLA LIMITED's last 90 days of official disclosures, balancing the constructive filings against the ones to watch. It is a signal from what the company has filed, not investment advice. Every line above links to its official exchange filing, and the full market desk is at the disclosures hub.
Key fundamentalsEditorial reference
The anchor data BazaarBaazi references when reading the CIPLA chart. Not a substitute for a registered research note.
| Ticker | CIPLA |
|---|---|
| Full name | Cipla Limited |
| Sector | Pharmaceuticals |
| Index class | LARGE CAP |
| ISIN | INE059A01026 |
| Market-cap band | ~1.1 lakh cr |
| Last referenced level | Inside latest show |
| Last session move | Not referenced this cycle |
| Editorial line in | Systematic Read on 9 Jun 2026 |
| Aliases tracked | CIPLA |
Reference chart2 Jan 2026
The daily frame the desk reads on CIPLA.
FAQ14 reader questions · AEO-eligible
The line on CIPLA, distilled and schema-marked for AI Overview, Perplexity, and reader search.
What is the CIPLA share price target for 2026?
BazaarBaazi does not publish a SEBI-registered price target on CIPLA. The desk reads structural support and resistance inside each show against the printed spot; the most recent editorial line is Systematic Read on 9 Jun 2026.
What is BazaarBaazi's Crack Score for CIPLA?
The BazaarBaazi Crack Score for CIPLA is 76 out of 100 as of 9 Jun 2026, a high conviction reading. It is a computed conviction number from the signed stance, how consistent the recent verdicts have been, the quality of the printed structure, and how fresh the review is. It is a transparency signal, not investment advice.
What is the F&O view on CIPLA?
As of 9 Jun 2026, BazaarBaazi reads CIPLA positioning as a two-way range write. This is a structural reading of the option chain, not a derivatives recommendation.
What sector is CIPLA in and which peers does BazaarBaazi track?
CIPLA sits in Pharmaceuticals (large cap), indicative market cap ~1.1 lakh cr, ISIN INE059A01026. The peers BazaarBaazi reads alongside it are Sun Pharmaceutical Industries Limited, Dr. Reddy's Laboratories Limited, Divi's Laboratories Limited. A systematic, data-only read on Cipla Limited: where it trades versus its 50-day and 200-day lines, the live 52-week range, and momentum. Refreshed from real price structure each run.
How often is the CIPLA view updated?
This page is one evergreen URL refreshed in place. The Crack Score and levels re-compute on every BazaarBaazi end-of-day run, and the dated stamp shows the last refresh. The latest signed verdict on CIPLA is mixed, published in Systematic Read on 9 Jun 2026.
Is Cipla a good long-term stock?
The structural case is built on complex-inhaler expertise and a chronic-therapy India franchise harder to displace than commodity generics, but the risk no score captures is that the key US inhaler approvals can stall on the regulator's timeline, not Cipla's. BazaarBaazi's Crack Score for CIPLA captures the current setup. The long-term view depends on US complex inhaler approval velocity and regulatory risk management.
Cipla share price target 2030?
What drives CIPLA through 2030 is gAdvair and complex-inhaler approvals scaling in the US, India branded compounding, and biosimilars adding a layer, with the catch that approval timing is set by the USFDA and no target can fix the calendar. BazaarBaazi does not publish fixed multi-year targets. The dated Crack Score is the right entry point.
Why is Cipla share falling?
Weakness in CIPLA usually starts with the triggers the desk watches first, a USFDA observation on a key facility or US inhaler approval delays, with an India volume miss or South Africa slowdown adding to it. The Crack Score levels have the technical picture.
What was CIPLA LIMITED's Q4 FY26 net profit?
CIPLA LIMITED reported a net profit of Rs 543 cr for Q4 FY26 (the quarter ended 31 March 2026). That is -55.3% year on year. The figure is from the company's official NSE filing.
What was CIPLA LIMITED's Q4 FY26 revenue?
CIPLA LIMITED reported revenue of Rs 6,541 cr for Q4 FY26. That is -2.8% year on year. The figure is from the company's official NSE filing.
How does BazaarBaazi rate CIPLA LIMITED's Q4 FY26 result?
BazaarBaazi gives CIPLA LIMITED's Q4 FY26 result a Result Pulse of 24 out of 100, with a verdict of Weak. The Result Pulse is a BazaarBaazi editorial score for the quality of the filed result, not investment advice.
What has Cipla Ltd announced recently?
Cipla Ltd's two most material recent disclosures are a dividend dated 08 Jun 2026, "communication on tax deduction at source on final…", and a disclosure dated 04 Jun 2026, "Allotment of 44770 Shares". Both link to the company's own official filing on the BazaarBaazi stock page.
Has Cipla Ltd declared a dividend recently?
Yes. Cipla Ltd filed a dividend disclosure on 08 Jun 2026, filed as "communication on tax deduction at source on final dividend for FY…". Any amount shown is the exchange's own record, linked from the BazaarBaazi stock page. A dividend is a declared payout, not a forecast of future returns.
What did Cipla Ltd's latest board meeting cover?
Cipla Ltd's most recent board-meeting disclosure on record dated 01 Jun 2026 reads "Notice of Annual General Meeting to be held on Jun 25, 2026". That is the agenda as filed with the exchange, linked from the BazaarBaazi stock page, and BazaarBaazi adds no claim of its own to it.
Related stock views
The names BazaarBaazi reads alongside CIPLA, each a living view refreshed every end-of-day run.
Hub
All stock views
The full BazaarBaazi coverage universe, scored and dated.
Pharmaceuticals
SUNPHARMA
Sun Pharmaceutical Industries Limited
Pharmaceuticals
DRREDDY
Dr. Reddy's Laboratories Limited
Pharma APIs and CDMO
DIVISLAB
Divi's Laboratories Limited
Pharmaceuticals
TORNTPHARM
Torrent Pharmaceuticals Limited
Pharmaceuticals
ZYDUSLIFE
Zydus Lifesciences Limited